The fumaric acid ester BG-12: A new option in MS therapy

Expert Review of Neurotherapeutics

Volumn 13, Issue 8, 2013, Pages 951-958

  Lee, De Hyung ^a   Stangel, Martin ^b   Gold, Ralf ^c   Linker, Ralf Andreas ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c ST JOSEF HOSPITAL   (Germany)

Author keywords

BG 12; clinical trial; dimethyl fumarate; Fumaric acid ester; immunomodulation; multiple sclerosis; neuroprotection

Indexed keywords

FUMADERM; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER;

DIARRHEA; DISABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FLUSHING; HUMAN; LEUKOCYTE COUNT; MULTIPLE SCLEROSIS; NAUSEA; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEINURIA; PRURITUS; RECURRENCE RISK; REVIEW; RISK FACTOR; SIDE EFFECT; UPPER ABDOMINAL PAIN;

ANIMALS; FUMARATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84882750579     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2013.814958     Document Type: Review

References (59)

1. Schweckendieck W. Treatment of psoriasis vulgaris. Med. Monatsschr. 13, 103-104 (1959
2. Nast A, Boehncke WH, Mrowietz U et al.; Deutsche Dermatologische Gesellschaft; Berufsverband Deutscher Dermatologen. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch. Dermatol. Res. 304(2), 87-113 (2012
3. Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T. Efficacy and safety of fumaric acid esters in the long-Term treatment of psoriasis-A retrospective study (FUTURE). J. Dtsch. Dermatol. Ges. 7(7), 603-611 (2009
4. Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int. J. Clin. Pract. 61(11), 1922-1930 (2007
5. Lassaigne. Ann. Chim. Phys. 11, 93 (1819
6. Litjens NH, Burggraaf J, van Strijen E et al. Pharmacokinetics of oral fumarates in healthy subjects. Br. J. Clin. Pharmacol. 58(4), 429-432 (2004
7. Rostami-Yazdi M, Clement B, Mrowietz U. Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch. Dermatol. Res. 302(7), 531-538 (2010
8. Litjens NH, van Strijen E, van Gulpen C et al. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol. 4, 22 (2004
9. Nibbering PH, Thio B, Zomerdijk TP, Bezemer AC, Beijersbergen RL, van Furth R. Effects of monomethylfumarate on human granulocytes. J. Invest. Dermatol. 101(1), 37-42 (1993
10. Werdenberg D, Joshi R, Wolffram S, Merkle HP, Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm. Drug Dispos. 24(6), 259-273 (2003
11. Itoh K, Wakabayashi N, Katoh Y et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-Terminal Neh2 domain. Genes Dev. 13(1), 76-86 (1999
12. Satoh T, Okamoto SI, Cui J et al. Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers. Proc. Natl. Acad. Sci. U.S.A. 103(3), 768-773 (2006
13. Satoh T, Harada N, Hosoya T, Tohyama K, Yamamoto M, Itoh K. Keap1/Nrf2 system regulates neuronal survival as revealed through study of keap1 gene-knockout mice. Biochem. Biophys. Res. Commun. 380(2), 298-302 (2009
14. Wakabayashi N, Itoh K, Wakabayashi J et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet. 35(3), 238-245 (2003
15. Chen PC, Vargas MR, Pani AK et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc. Natl. Acad. Sci. U.S.A. 106(8), 2933-2938 (2009
16. Duffy S, So A, Murphy TH. Activation of endogenous antioxidant defenses in neuronal cells prevents free radical-mediated damage. J. Neurochem. 71(1), 69-77 (1998
17. Ellrichmann G, Petrasch-Parwez E, Lee DH et al. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS ONE 6(1), e16172 (2011
18. Hubbs AF, Benkovic SA, Miller DB et al. Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2. Am. J. Pathol. 170(6), 2068-2076 (2007
19. Khodagholi F, Eftekharzadeh B, Maghsoudi N, Rezaei PF. Chitosan prevents oxidative stress-induced amyloid beta formation and cytotoxicity in NT2 neurons: Involvement of transcription factors Nrf2 and NF-kappaB. Mol. Cell. Biochem. 337(1-2), 39-51 (2010
20. Kim YS, Podder B, Song HY. Cytoprotective effect of alpha-lipoic acid on paraquatexposed human bronchial epithelial cells via activation of nuclear factor erythroid related factor-2 pathway. Biol. Pharm. Bull. 36(5), 802-811 (2013
21. Kraft AD, Johnson DA, Johnson JA. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J. Neurosci. 24(5), 1101-1112 (2004
22. Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J. Biol. Chem. 278(14), 12029-12038 (2003
23. Lewerenz J, Albrecht P, Tien ML et al. Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro. J. Neurochem. 111(2), 332-343 (2009
24. Liu Y, Kern JT, Walker JR, Johnson JA, Schultz PG, Luesch H. A genomic screen for activators of the antioxidant response element. Proc. Natl. Acad. Sci. USA. 104(12), 5205-5210 (2007
25. Rachakonda G, Xiong Y, Sekhar KR, Stamer SL, Liebler DC, Freeman ML. Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3. Chem. Res. Toxicol. 21(3), 705-710 (2008
26. Sasaki S, Tozawa T, Sugamoto K, Matsushita YI, Satoh T. A novel di terpene para-hydroquinone compound derived from cryptoquinone protects neuronal cells against oxidative stress and activates the Nrf2/ARE pathway. Neurosci. Lett. (2013
27. Scannevin RH, Chollate S, Jung MY et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J. Pharmacol. Exp. Ther. 341(1), 274-284 (2012
28. Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin. Exp. Immunol. 145(1), 101-107 (2006
29. Stewart D, Killeen E, Naquin R, Alam S, Alam J. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. J. Biol. Chem. 278(4), 2396-2402 (2003
30. Su JY, Duffy S, Murphy TH. Reduction of H2O2-evoked, intracellular calcium increases in the rat N18-RE-105 neuronal cell line by pretreatment with an electrophilic antioxidant inducer. Neurosci. Lett. 273(2), 109-112 (1999
31. Tabrizi SJ, Workman J, Hart PE et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 47(1), 80-86 (2000
32. Thiessen A, Schmidt MM, Dringen R. Fumaric acid dialkyl esters deprive cultured rat oligodendroglial cells of glutathione and upregulate the expression of heme oxygenase 1. Neurosci. Lett. 475(1), 56-60 (2010
33. Yang L, Calingasan NY, Thomas B et al. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS ONE 4(6), e5757 (2009
34. Yu M, Xu M, Liu Y et al. Nrf2/ARE is the potential pathway to protect Sprague-Dawley rats against oxidative stress induced by quinocetone. Regul. Toxicol. Pharmacol. 66(3), 279-285 (2013
35. Linker RA, Lee DH, Ryan S et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134(Pt 3), 678-692 (2011
36. de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur. J. Immunol. 26(9), 2067-2074 (1996
37. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br. J. Dermatol. 139(3), 390-395 (1998
38. Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem. Biophys. Res. Commun. 234(1), 19-23 (1997
39. Rubant SA, Ludwig RJ, Diehl S et al. Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. J. Invest. Dermatol. 128(2), 326-331 (2008
40. Gerdes S, Shakery K, Mrowietz U. Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/ enhancer binding protein beta in activated human T cells. Br. J. Dermatol. 156(5), 838-842 (2007
41. Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: More than a dietary curiosity. Trends Mol. Med. 11(1), 43-48 (2005
42. Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J. Invest. Dermatol. 116(2), 203-208 (2001
43. Loewe R, Holnthoner W, Gröger M et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J. Immunol. 168(9), 4781-4787 (2002
44. Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-Alpha and IL-6 in an in-vitro model of brain inflammation. J. Neuroinflammation 7, 30 (2010
45. Ghoreschi K, Brück J, Kellerer C et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J. Exp. Med. 208(11), 2291-2303 (2011
46. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy. J. Neurol. 251(3), 261-268 (2004
47. Johnson DA, Amirahmadi S, Ward C, Fabry Z, Johnson JA. The absence of the pro-Antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. Toxicol. Sci. 114(2), 237-246 (2010
48. Berer K, Mues M, Koutrolos M et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479(7374), 538-541 (2011
49. Esplugues E, Huber S, Gagliani N et al. Control of TH17 cells occurs in the small intestine. Nature 475(7357), 514-518 (2011
50. Kleinewietfeld M, Manzel A, Titze J et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 496(7446), 518-522 (2013
51. Schimrigk S, Brune N, Hellwig K et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: An open-label, baseline-controlled pilot study. Eur. J. Neurol. 13(6), 604-610 (2006
52. Kappos L, Gold R, Miller DH et al.; BG-12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372(9648), 1463-1472 (2008
53. Kappos L, Gold R, Miller DH et al. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: Subgroup analyses from the phase 2b study. Mult. Scler. 18(3), 314-321 (2012
54. MacManus DG, Miller DH, Kappos L et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J. Neurol. 258(3), 449-456 (2011
55. Gold R, Kappos L, Arnold DL et al.; DEFINE Study Investigators. Placebocontrolled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367(12), 1098-1107 (2012
56. Fox RJ, Miller DH, Phillips JT et al.; CONFIRM Study Investigators. Placebocontrolled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367(12), 1087-1097 (2012
57. Hanson J, Gille A, Offermanns S. Role of HCA2 (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin. Pharmacol. Ther. 136(1), 1-7 (2012
58. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N. Engl. J. Med. 368(17), 1657-1658 (2013
59. Sweetser MT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. N. Engl. J. Med. 368(17), 1659-1661 (2013